AUTHORS
Aung M. Tun, MD, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Cameron J. Turtle5, Peter Riedell, MD6, Craig Sauter, MD7, Alex Francisco Herrera, MD8, Mehdi Hamadani, MD9, Mazyar Shadman, MD, MPH10, Madiha Iqbal, MBBS, MD11
AFFILIATIONS
1 University of Kansas Cancer Center, Kansas City, KS, USA, Westwood, Kansas, United States
2 Medical College of Wisconsin,, Milwaukee, United States
3 Medical College of Wisconsin,, Milwaukee, United States
4 Medical College of Wisconsin,, Milwaukee, United States
5 University of Sydney, Camperdown, New South Wales, Australia
6 University of Chicago Medical Center, Chicago, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 City of Hope, Duarte, United States
9 Medical College of Wisconsin,, Milwaukee, United States
10 Fred Hutchinson Cancer Center, Seattle, United States
11 Mayo Clinic, Jacksonville, United States
ABSTRACT
Introduction: Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of aggressive extranodal lymphoma. Intensive induction regimens are often prescribed, but prognosis is poor without hematopoietic cell transplantation (HCT). Data regarding post HCT outcomes, prognostic factors, and consolidation strategies – particularly the relative roles of allogeneic (allo)-HCT vs autologous (auto)-HCT – remain limited. Therefore, we sought to study patients with HSTCL from the CIBMTR registry.
Methods: Patients with HSTCL who underwent their first auto- or allo-HCT between 2008 and 2024 and had data reported to CIBMTR were included in this study. The primary endpoint was overall survival (OS; time from HCT to death). Secondary endpoints included progression-free survival (PFS; time from HCT to disease relapse/progression or death), and rates of relapse and non-relapse mortality (NRM).
Results: 271 patients were included; (allo-HCT=220, auto-HCT=51 ). Median age at HCT was 37.2 years (range 4.9–77.0); 179 patients (66.1%) were male; 156 (57.6%) were white; and 91 (33.6%) had a Karnofsky score of <90. The HCT-specific comorbidity index score was ≥3 in 100 patients (36.9%). Most patients (58.1%, n=79) had 1 prior line of therapy; 166 (61.3%) were in complete remission (CR) and 71 (26.2%) were in partial remission (PR) prior to HCT. Median time from diagnosis to HCT was 5.3 months (range 1.2–57.8), and 232 (86.0%) patients had HCT within ≤12 months of diagnosis.
Among allo-HCT recipients, the majority received myeloablative conditioning (66.4%, n=146). Most patients underwent allo-HCT from a matched unrelated (43.2%, n=95) or related (32.3%, n=71) donor. For graft-versus-host disease (GVHD) prophylaxis, calcineurin inhibitor-based regimens were frequently used (57.7%, n=127), followed by post-transplant cyclophosphamide (31.4%, n=69). Among auto-HCT recipients, carmustine, etoposide, cytarabine, and melphalan (BEAM) or a BEAM-like conditioning regimen was used in most patients (62.7%, n=32).
The 28-day rates of neutrophil recovery among auto-HCT and allo-HCT recipients were 100.0% (95% confidence interval [CI] 0.0–100.0) and 95.9% (95% CI 92.8–98.2), respectively. The corresponding 100-day rates of platelet count recovery were 100.0% (95% CI 0.0–100.0) and 93.2% (95% CI 89.3–96.3). In allo-HCT recipients, the 180-day rates of grade 2-4 and grade 3-4 acute GVHD were 28.5% (95% CI 22.3–35.2) and 10.5 (95% CI 6.6–15.2), respectively. The 1-year incidence of chronic GVHD was 31.6% (95% CI, 25.5–38.1).
In the auto-HCT cohort, 3-year OS, PFS, relapse rates, and NRM were 48.6% (95% CI 34.0–63.3), 37.2% (95% CI 23.2–52.4), 50.8% (95% CI 35.4–66.1), and 12.0% (95% CI 3.9–23.7), respectively. Among allo-HCT recipients, 3-year OS, PFS, relapse rates, and NRM were 53.4% (95% CI 46.3–60.4), 48.3% (95% CI 41.2–55.4), 36.9% (95% CI 30.4–43.7), and 14.8% (95% CI 10.1–20.2), respectively. GVHD free, relapse free survival was 30.6% (95% CI 24.1–37.6) at 3 years for recipients of allo-HCT.
Among auto-HCT recipients, a Karnofsky score of <90 was associated with inferior PFS (hazard ratio [HR], 2.29; 95% CI 1.05–5.00; P=0.04) but not OS (HR, 1.49; 95% CI 0.69–3.22; P=0.31). In addition, patients in PR prior to HCT, compared to those in CR, had significantly worse PFS (HR, 4.47; 95% CI 1.71–11.68; P<0.01).
In the multivariate analysis of the larger allo-HCT cohort, disease status at transplantation was independently associated with outcomes. Compared to patients achieving CR, PR at allo-HCT was associated with inferior OS (HR, 1.74; 95% CI 1.13–2.67; P=0.01) and PFS (HR, 1.87; 95% CI 1.23–2.85; P=0.00). Similarly, patients with chemoresistant/untreated disease at allo-HCT had worse OS (HR, 1.89; 95% CI 1.13–3.17; P=0.02) and PFS (HR, 1.92; 95% CI 1.16–3.17; P=0.01) compared with those in CR.
Conclusions: Durable remission can be achieved with HCT in patients with HSTCL. Failure to achieve CR prior to HCT is a strong independent risk factor for poor OS and PFS after auto- or allo-HCT. Aggressive induction regimens incorporating novel therapeutic agents should be studied in this patient population. Although this study is not designed to compare outcomes of auto-HCT and allo-HCT recipients, allo-HCT appears to have numerically higher 3-year PFS rates and may be the preferred modality in eligible patients.
DISCLOSURES
Aung M. Tun, MD: Curio Science - Honoraria; Acrotech - Consultancy (Includes expert testimony); KUMC - Current Employment